Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.50
Bid: 1,604.00
Ask: 1,604.50
Change: 4.50 (0.28%)
Spread: 0.50 (0.031%)
Open: 1,600.50
High: 1,612.50
Low: 1,591.00
Prev. Close: 1,595.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

RPT-Fitch Revises Bayer AG'S Outlook to Negative; Affirms at 'A'

Thu, 08th May 2014 12:58

(Repeat for additional subscribers)

May 8 (Reuters) - (The following statement was released by the rating agency)

Fitch Ratings has revised Germany-based healthcare company Bayer AG's Outlook toNegative from Stable. The agency has also affirmed its Long-term Issuer Default Rating (IDR) andsenior unsecured rating at 'A', its Short-term IDR at 'F1', and its hybrid instrument rating at'BBB+'.

The rating action follows Bayer's offer to acquire the consumer healthcare division from Merck & Co Inc (Merck) for USD14.2bn. In addition to this announcement, Bayer has entered into collaboration with Merck in cardiovascular therapeutic developments (sGC modulators), which will result in an USD1bn upfront payment to Bayer and additional sales milestones payments depending on R&D success. Based on Fitch's projections the company post acquisition would have exhausted its financial flexibility and we would expect a period of deleveraging for the rating to remain at its 'A' level, to which management have reiterated their commitment.

The announced transaction is expected to be fully debt-funded by way of senior and hybrid debt issues (split to be determined) and is subject to regulatory approvals with expected completion in 2H14.

KEY RATING DRIVERS

Acquisition to Increase Leverage

The Negative Outlook reflects an expected increase in leverage due to the debt-financed acquisition of Merck's consumer health care division. Fitch projects around a 1.2x increase in funds from operations (FFO) adjusted net leverage to an annualised peak of around 2.5x post acquisition, incorporating also the earlier acquisition of Norway-based pharma company, Algeta ASA, for around USD2.6bn and announced plans to acquire Dihon Pharmaceutical Group Co., Ltd., based in China. Such a financial profile is not compatible with the current 'A' rating given Bayer's underlying business risk profile.

Strategic Fit and Improving Business Profile

Fitch considers the proposed acquisition of the Merck consumer health assets a sound strategic fit as it enables Bayer to significantly boost its product range and geographical reach in this segment. The Bayer/Merck combination will regain the No 2 global market position in the consumer health segment (behind the recently announced Novartis/GSK combination and ahead of Johnson & Johnson).

Accordingly, Fitch believes the business risk profile will improve as a result of the transaction as it will strengthen the competitive position of its consumer healthcare division in a rapidly consolidating market, and improve the overall diversification of the group.

Active Management of R&D Risks

The strategic collaboration in the cardio-vascular therapeutic area will combine two complementary and promising pipelines in cardio-vascular treatment with a view to lowering the cost and risks of bringing products to market. This combination should result in an enhanced R&D success probability for both companies.

Synergies and Tax Benefits

Fitch believes that the transaction will be margin-enhancing and offer considerable revenue synergies in addition to some cost savings. However we have not factored a significant upside in our forecasts due to the inherent execution risk in extracting such benefits. In addition, it will lower the group's overall tax rate by structuring the transaction as an 'asset' rather than an 'entity' purchase.

Fitch, however, highlights significant uncertainties associated with this transaction that could affect the rating level of Bayer post completion. These include delays in achieving the estimated margin improvement; long-term debt structure post completion and associated financing costs; benefits arising from the strategic cardio-vascular collaboration agreement; and details around tax benefits (which the company has not yet finalised).

RATING SENSITIVITIES

A change of the Outlook back to Stable is contingent on a return to an improved financial leverage profile with FFO adjusted net leverage below 2.0x on a sustained basis, resulting from a smooth integration of the acquisition supported by other cash preservation measures, and FFO fixed charge cover of above 8.0x within the next 12 to 18 months.

Sustained financial ratios worse than above indicated levels i.e. as a result of lower-than- expected cost savings and/or revenue uplift or a permanently higher debt burden could result in a rating downgrade. At present, a potential downgrade would be limited to one notch.

More News
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more
14 Nov 2023 17:04

LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI

(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.

Read more
13 Nov 2023 09:47

GSK hails momelotinib opinion from European Medicines Agency committee

(Alliance News) - GSK PLC on Monday announced that a European Medicines Agency panel has given a positive opinion recommending momelotinib to treat myelofibrosis patients with anaemia.

Read more
9 Nov 2023 15:50

UK dividends calendar - next 7 days

Friday 10 November 
Bodycote PLCdividend payment date
Breedon Group PLCdividend payment date
Chesnara PLCdividend payment date
Finsbury Growth & Income Trust PLCdividend payment date
Invesco Bond Income Plus Ltddividend payment date
JPMorgan Emerging Markets Investment Trust PLCdividend payment date
Kerry Group PLCdividend payment date
Merchants Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCspecial dividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Senior PLCdividend payment date
Spectris PLCdividend payment date
Spirax-Sarco Engineering PLCdividend payment date
Travis Perkins PLCdividend payment date
Monday 13 November 
no events scheduled 
Tuesday 14 November 
no events scheduled 
Wednesday 15 November 
Coats Group PLCdividend payment date
Ferguson PLCdividend payment date
JP Morgan Mid Cap Investment Trust PLCdividend payment date
Strategic Equity Capital PLCdividend payment date
Thursday 16 November 
abrdn Property Income Trust Ltdex-dividend payment date
Asian Energy Impact Trust PLCex-dividend payment date
Baillie Gifford Japan Trust PLCex-dividend payment date
BlackRock Greater Europe Investment Trust PLCex-dividend payment date
Bunzl PLCex-dividend payment date
Bytes Technology Group PLCex-dividend payment date
Centrica PLCdividend payment date
Coca-Cola Europacific Partners PLCex-dividend payment date
DX Group PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
GCP Asset Backed Income Fund Ltdex-dividend payment date
GSK PLCex-dividend payment date
Hargreaves Lansdown PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
ICG Enterprise Trust PLCex-dividend payment date
James Halstead PLCex-dividend payment date
Lancashire Holdings Ltdspecial ex-dividend payment date
Majedie Investments PLCex-dividend payment date
Marks & Spencer Group PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
New Star Investment Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Personal Group Holdings PLCdividend payment date
Redrow PLCdividend payment date
Regional REIT Ltdex-dividend payment date
Schroder Oriental Income Fund Ltdex-dividend payment date
Scottish American Investment Co PLCex-dividend payment date
SCS Group PLCex-dividend payment date
Shell PLCex-dividend payment date
Supermarket Income REIT PLCdividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
Unilever PLCex-dividend payment date
Wincanton PLCex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
8 Nov 2023 09:30

LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
2 Nov 2023 10:14

LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.